mt-3995
Small moleculeexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01756703)
Timeline
Indications
Mechanism of action
- Mineralocorticoid receptorANTAGONIST
NR3C2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(c2ccc(F)cc2)C1=O- Mol. weight
- 364.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545392 ↗
- ChEMBLCHEMBL2181929 ↗
Also known as
- mt-3995
- mt-3995
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02923154 | Phase 2 | Sep 1, 2016 | Mitsubishi Tanabe |
| NCT02900235 | Phase 1 | Aug 1, 2016 | Mitsubishi Tanabe |
| NCT02676401 | Phase 2 | Feb 1, 2016 | Mitsubishi Tanabe |
| NCT02517320 | Phase 2 | Jul 1, 2015 | Mitsubishi Tanabe |
| NCT02531568 | Phase 1 | Jun 1, 2015 | Mitsubishi Tanabe, Nuvisan Pharma Services |
| NCT02205372 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2014 | Mitsubishi Tanabe, University of Tokyo |
| NCT01889277 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | Mitsubishi Tanabe, University of Tokyo |
| NCT01756716 | Phase 2 | Dec 1, 2012 | Mitsubishi Tanabe |
| NCT01756703 | Phase 2 | Nov 1, 2012 | Mitsubishi Tanabe |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mitsubishi Tanabe | For profit | 9 | 9 | 2 | 2012 |
| University of Tokyo | Academic/Hospital | 2 | 0 | 1 | 2013 |
| Nuvisan Pharma Services | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1